Agenda
Flip through our conference brochure and discover what’s new this year.
Download Brochure
Day 1 — Main Conference
March 10, 2026
Registration Opens & Attendee Ice-Breaker Activity
Welcome Breakfast Sponsored by 

Ana Garcia BelloVice President Law MedTech EMEAJohnson & JohnsonBelgium

Bibianne BonChief Legal OfficerRecordati SpaItaly

Arianna GrecoSenior Vice President and General Counsel for R&D and CommercialAlnylam PharmaceuticalsSwitzerland
Business Beyond Borders: Global Opportunities and Challenges in Life Sciences – And What They Mean for Europe

Lena Moran AdamsGroup General CounselTelix Pharmaceuticals United Kingdom

Amy AltshulHead of Legal, International BusinessesNovartisSwitzerland

Anna RolovaAssistant General Counsel, OncologyGSKBelgium

Abena Danso AlloteyDeputy Head Legal & Compliance Region Europe and InternationalSandozUnited Arab Emirates

Luciana GriebelPartnerMorgan, Lewis & Bockius UK LLPUnited Kingdom
The global competitive landscape for life sciences is evolving. Geopolitical developments and the increasing importance of emerging markets, including China, India and the Middle East, are resulting in significant headwinds for the European life sciences sector. Kicking off the 2nd annual Summit, life sciences leaders from key global jurisdictions will discuss the opportunities and challenges of the rapidly evolving landscape and the implications for European-based organizations.
Networking and Refreshment Break
Strategies for Safeguarding Operations and Minimizing Global Supply Chain Disruption Amidst Tariff Volatility and Evolving Manufacturing Requests

Lisa KinsellaVice President, Associate General CounselModernaSwitzerland

Ksenia MikhailovaSenior Legal Counsel Trade SanctionsNovartisUnited Kingdom

Priscilla TatschnerPartnerClifford ChanceGermany

Alessandro GangarossaDirectorGlobal CounselBelgium
Global trade turbulence is presenting new supply chain management challenges for life sciences companies. With ongoing uncertainty around tariffs, companies must adapt how they source, manufacture and distribute critical products. As the regulatory and economic pressures on crossborder operations mount, this session will explore practical ways to navigate these global trade pressures and keep supply chains resilient and compliant.
Key discussion areas include:
- Assessing the impact of current tariffs on life sciences company supply chains and key considerations for compliance.
- Strategies for supply chain diversification to reduce dependency on high-risk markets.
- How companies are renegotiating trade agreements and leveraging alternative sourcing solutions.
Networking Lunch – with facilitated leadership table topics
CONCURRENT BREAKOUT SESSIONS (Choose A or B)
BREAKOUT A
EU Pharma Package: Practical Implementations Strategies for Immediate and Long-Term Action

Sarah ForestSenior Director - Regulatory Law EMEAJohnson & JohnsonBelgium

Elisabeth LeimbacherGlobal Legal Lead Marketing & Commercial ExcellenceTakeda PharmaceuticalsSwitzerland

Delphine MarchalAssociate Vice President, Assistant General Counsel, Regulatory Legal TeamEli Lilly and Company Belgium

Charlotte RyckmanEurope Head, Clinical R&D and Regulatory LegalAbbVieBelgium

Marie ManleyPartner, Head of Life Sciences RegulatoryHerbert Smith Freehills Kramer LLPUnited Kingdom
The proposed reforms under the EU Pharma Package will have significant operational, financial, and strategic implications for companies across the life sciences sector. This session focuses on the practical realities of implementation—exploring how companies of different types and sizes are interpreting and preparing for the changes, and what action should be taken now versus in the longer term.
Key discussion areas include:
- Assessing the package’s impact and prioritizing compliance while protecting innovation pipelines.
- Budgeting and resource allocation – budget distribution for R&D, regulatory readiness, and product lifecycle management under the new framework.
- Real-world approaches to sequencing implementation steps, coordinating with cross-functional teams, and balancing compliance demands with commercial imperatives.

Nicola FowlerCompliance Counsel and Global Data Protection OfficerBioMarin Ireland

Nanna JannovVice President, R&D Ethics & ComplianceNovo NordiskDenmark

Leticia LizardoGeneral CounselLuxembourg Institute of Health Luxembourg
As Europe advances its data regulatory framework, life sciences companies face both heightened compliance responsibilities and unprecedented opportunities for innovation. This session will unpack the latest developments in EU data legislation. Learn from leading attorneys as they explore practical strategies for managing sensitive patient and research data, fostering trust with stakeholders, and unlocking value from secondary data use—all while staying ahead of regulatory change. Participants will gain insights into balancing privacy with progress, collaborating across borders, and positioning their organizations to thrive in Europe’s rapidly evolving data ecosystem.
CONCURRENT BREAKOUT SESSIONS (Choose A or B)

Caroline StockwellVice President, Head of Legal – InternationalAmicus TherapeuticsUnited Kingdom

Koosje Van Lessen KloekeAdvocaatLeijnse ArtzThe Netherlands

Zoe KimberlyArea Counsel, EuropeAbbVieUnited Kingdom

Sophie PeléPartnerDechert LLPFrance
The external environment and policy shaping is more important than ever for Pharma. The Trump administration’s ‘Most-Favored Nation’ (MFN) initiative intersects heavily with the EU Pharma Package (GPL). In Europe we face increasingly complex legislative reform with the Critical Medicines Act and Biotech Act in addition to the GPL and new HTA requirements.
This session examines the key issues and how in house teams should prepare themselves to face the challenges (but also opportunities) that the current ever evolving environment represents.

Lien DelvoyeSenior Legal DirectorJohnson & JohnsonBelgium

Afua van HaasterenDirector, Health Policy & External AffairsRoche DiagnosticsSwitzerland

Georgina KonPartnerLinklaters LLPUnited Kingdom

Karin PrambergerHead of IPPolpharma GroupSwitzerland
Artificial intelligence is rapidly reshaping every stage of the life sciences value chain—from research to commercialization. This session will showcase how organizations are applying AI in practice, the benefits and risks they’re encountering, and the critical considerations for driving successful adoption. Attendees will also gain insight into the governance frameworks and best practices needed to ensure AI is integrated responsibly and effectively.
Key discussion areas include:
- Highlighting the expanding role of AI in the daily operations of life sciences, from drug discovery and development, to regulatory submission and monitoring manufacturing and supply, clinical trials, and ultimately commercial launch and patient outcomes.
- Adoption considerations for pharma, biotech and MedTech, including industry regulation, alignment on value, capacity to execute, and effective change management.
- Raising awareness of the key challenges for successful AI integration, such as data governance, intellectual property protection, avoiding bias, and anticipating or mitigating potential liabilities.
- AI governance best practices – defining acceptance use policies and processes for ongoing monitoring of use.
Networking and Refreshment Break
Leading through Times of Change and Uncertainty: Navigating Shifting Regulatory Landscapes and an Unpredictable Macro Environment

Anne-Sophie BriccaDeputy General Counsel – International BusinessTerumo BCT Europe NV Belgium

Kristine PeersGeneral CounselEFPIA - European Federation of Pharmaceutical Industries and AssociationsBelgium

Angelika SedlackovaGeneral Counsel for EU CommercialTeva PharmaceuticalsThe Netherlands

Ana Garcia BelloVice President Law MedTech EMEAJohnson & JohnsonBelgium
In today’s volatile environment—marked by evolving regulations, geopolitical shifts, and economic unpredictability—the role of legal counsel is expanding well beyond risk management. This session will explore how legal leaders can not only adapt but lead with confidence, clarity, and influence.
Key discussion areas include:
- Repositioning the role of the general counsel – moving from a traditional legal advisor to a trusted strategic partner in shaping business direction.
- Strengthening alignment and communication with business leaders – building trust to ensure legal priorities are embedded in strategic planning.
- Navigating pressure from business leaders with legal and compliance risk – finding the right balance.
- Leading with resilience and vision – demonstrating adaptability within the legal team, maintaining morale during global instability and decisive leadership under pressure.
Networking Reception
Day 2 — Main Conference
March 11, 2026
Registration Opens and Breakfast Available

Lena Moran AdamsGroup General CounselTelix Pharmaceuticals United Kingdom
Grab a coffee and breakfast and kick-start your day by leveraging the shared experiences and collective knowledge of your industry peers during these facilitated roundtable discussions. Attendees will pre-select the roundtable discussion topic they would like to participate in for the duration of the session.
- Hybrid/Remote Work Attitudes – 5 Years On
- Evolving Leadership Paradigm: What is Expected of a Leader Today
- The Family Dimension of Leadership: Balancing Personal and Professional Life
- Strategic Influence for Women: Personal Brand, Storytelling and Buy-In
- Is Feedback Really a Gift?
Networking and Refreshment Break

Angélique de BrousseHead of the Competition Law and Policy Group for EMEAJohnson & JohnsonBelgium

Annamaria MangiaracinaPartnerLinklaters LLPBelgium

Cláudia TrabucoGlobal Head of Competition LawGilead Portugal

Enrica SchaeferPartnerKirkland & Ellis LLPBelgium

Juliana NevesPartnerLicks AttorneysBrazil
Competition authorities in the EU and UK are increasingly incorporating innovation-based theories of harm into antitrust reviews and merger assessments—shifting the focus from traditional market share metrics to the potential impact on future competition and R&D pipelines. Other renewed points of focus include lifecycle management as well as marketing and price negotiation policies in the life sciences industry. This session will examine the implications for life sciences companies of this evolving approach, where innovation is both a key differentiator and a regulatory flashpoint.
Key discussion areas include:
- Determining how innovation-based theories of harm are influencing case outcomes and shaping the regulatory landscape.
- Leveraging economic analysis as a strategic tool to assess innovation potential, quantify competitive effects, and engage constructively with regulators.
- Building a defensible innovation narrative – practical guidance for documenting R&D strategy, collaboration models, and long-term market contributions to withstand regulatory scrutiny.
- Implications for transactions and partnerships – considerations for deal structures, joint ventures, or licensing arrangements in light of this evolving enforcement approach.
- Lifecycle management issues and challenges concerning optical marketing and pricing of pharmaceutical products within a competition law framework.
Networking Lunch

Malini MoorthiGeneral Counsel and Corporate Secretaryargenx Belgium

Lisa OwensManaging Director, In-House Counsel RecruitingMajor, Lindsey & AfricaUnited Kingdom

Janet RaimondoGlobal Head Legal TransactionsNovartisSwitzerland

Jerry TemkoManaging Director, In-House Counsel RecruitingMajor, Lindsey & Africa United Kingdom
As the expectations placed on senior legal leaders continue to evolve, success increasingly depends on the ability to influence beyond traditional legal expertise. This interactive session explores how legal leaders can position themselves as trusted strategic partners to the C-suite, driving value in an environment shaped by geopolitical uncertainty, regulatory complexity, and AI. Through practical insights and guided discussion, participants will gain insight into the skills, mindset, and personal positioning required to lead with influence at the highest levels of their organisation.
Key discussion areas include:
- Building influence across the C-suite by understanding power dynamics and the importance of commercial fluency
- Developing trust with CEOs, CFOs, Boards, and cross-functional leaders
- Strategically positioning yourself as a business partner through visibility, credibility, and personal brand
- Translating insights into action through leadership commitments that strengthen long-term impact and presence

Serena ter KulieLegal CounselAlesta TherapeuticsThe Netherlands

Sylvie Vanden BruelExecutive Legal Counsel – Head of Legal BD – M&AUCB Belgium

Kelly CurtinManaging Director, Global Healthcare GroupStifelUnited Kingdom

Haruka OkiharaCounselClifford ChanceGermany
In a competitive and highly regulated industry, life sciences commercial teams are increasingly looking beyond internal pipelines to fuel growth—investing in start-ups, securing licensing deals, and partnering with innovators. This session will explore how companies are structuring investments, from small equity stakes to strategic licensing agreements, to diversify risk and accelerate innovation.
Key discussion areas include:
- Addressing the challenges of relying on external R&D pipelines, including intellectual property considerations, cross-border regulatory compliance, and coordination complexities.
- Real-world approaches to evaluating targets, managing long-term IP rights, aligning timelines and priorities with external partners.
- Navigating the regulatory landscape to ensure growth strategies deliver lasting value.
Networking and Refreshment Break

Henar Alvarez Alonso-PesqueraAssociate Director, Legal International RegionAlnylam PharmaceuticalsSpain

Vasiliki ChristoforidouSenior Regional Counsel GSAStryker Germany

Veronika Hughes-BednarVice President, Global Head of Legal TransactionsAstellas Pharma Europe Ltd. United Kingdom

Eva KovačićGeneral Counsel and Chief Compliance OfficerBelupo Croatia
Life sciences teams are increasingly global, cross-functional, and multi-generational—bringing together diverse perspectives, skills, and communication styles. This interactive session will provide practical tools to bridge cultural and generational gaps, address unconscious bias, boost collaboration, and unlock the full potential of your team.
Key discussion areas include:
- Understanding how generational identities shape values, communication styles and career expectations.
- Identifying the distinct preferences for how different generations and cultures receive and process information and what influences their decision-making.
- Recognizing and mitigating unconscious bias to create a more inclusive, equitable, and high-performing team environment.
- Building bridges across differences with proven techniques to foster collaboration, knowledge-sharing, and mutual respect in culturally and generationally diverse teams.
- Applying emotional intelligence to influence and motivate teams.

Dulce GonçalvesAssistant General CounselTelix PharmaceuticalsSwitzerland

Ilja MoreeGlobal Head ERC for R&D, Operations and DPDAINovartis AGSwitzerland

Charlotte GarriguesVice President Law Innovative Medicine EMEAJohnson & JohnsonBelgium

Cristiana SpontoniGlobal Practice Co-Leader Health Care and Life SciencesJones DayBelgium
To close the 2nd annual Summit, we bring together an accomplished panel of women who have navigated the complex world of life sciences law and emerged as influential leaders. In this candid conversation, they’ll share defining moments, lessons learned, and the realities—both rewarding and challenging—of leadership. This session will be as much about practical wisdom as it is about inspiration, offering tangible takeaways for those seeking to lead and those already in the arena.
Key discussion areas include:
- Breaking barriers and challenging bias in traditionally male-dominated spaces.
- Leadership approaches that inspire trust, resilience, and results.
- Balancing ambition and wellbeing in a demanding sector.
- Turning career pivots into growth opportunities.
- Mentorship and paving the way for the next gen.eration of life sciences women leaders.





